BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Reynolds JA, McCarthy EM, Haque S, Ngamjanyaporn P, Sergeant JC, Lee E, Lee E, Kilfeather SA, Parker B, Bruce IN. Cytokine profiling in active and quiescent SLE reveals distinct patient subpopulations. Arthritis Res Ther 2018;20:173. [PMID: 30092845 DOI: 10.1186/s13075-018-1666-0] [Cited by in Crossref: 18] [Cited by in F6Publishing: 25] [Article Influence: 4.5] [Reference Citation Analysis]
Number Citing Articles
1 Shao L, Pelayo A, Shi R, Ma J, Liu H, Cai Y, Prochazkova M, Somerville RP, Panch SR, Shah NN, Stroncek DF, Jin P. Identification of genomic determinants contributing to cytokine release in immunotherapies and human diseases. J Transl Med 2022;20:338. [PMID: 35902861 DOI: 10.1186/s12967-022-03531-3] [Reference Citation Analysis]
2 Guthridge JM, Wagner CA, James JA. The promise of precision medicine in rheumatology. Nat Med 2022. [PMID: 35788174 DOI: 10.1038/s41591-022-01880-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Pan Z, Zhu T, Liu Y, Zhang N. Role of the CXCL13/CXCR5 Axis in Autoimmune Diseases. Front Immunol 2022;13:850998. [DOI: 10.3389/fimmu.2022.850998] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Sánchez ARP, Voskuyl AE, van Vollenhoven RF. Treat-to-target in systemic lupus erythematosus: advancing towards its implementation. Nat Rev Rheumatol 2022. [PMID: 35039665 DOI: 10.1038/s41584-021-00739-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
5 Hashemi S, Habibagahi Z, Heidari M, Abdollahpour-Alitappeh M, Karimi MH. Effects of combined aerobic and anaerobic exercise training on cytokine profiles in patients with systemic lupus erythematosus (SLE); a randomized controlled trial. Transpl Immunol 2021;70:101516. [PMID: 34922023 DOI: 10.1016/j.trim.2021.101516] [Reference Citation Analysis]
6 Cassidy MF, Herbert ZT, Moulton VR. Splicing factor SRSF1 controls distinct molecular programs in regulatory and effector T cells implicated in systemic autoimmune disease. Mol Immunol 2021;141:94-103. [PMID: 34839165 DOI: 10.1016/j.molimm.2021.11.008] [Reference Citation Analysis]
7 Li X, Shao M, Zeng X, Qian P, Huang H. Signaling pathways in the regulation of cytokine release syndrome in human diseases and intervention therapy. Signal Transduct Target Ther 2021;6:367. [PMID: 34667157 DOI: 10.1038/s41392-021-00764-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
8 Dörner T, Tanaka Y, Petri MA, Smolen JS, Wallace DJ, Dow ER, Higgs RE, Rocha G, Crowe B, Benschop RJ, Byers NL, Silk ME, de Bono S, Fantini D, Hoffman RW. Baricitinib-associated changes in global gene expression during a 24-week phase II clinical systemic lupus erythematosus trial implicates a mechanism of action through multiple immune-related pathways. Lupus Sci Med 2020;7:e000424. [PMID: 33037080 DOI: 10.1136/lupus-2020-000424] [Cited by in Crossref: 7] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
9 Yan C, Yu L, Zhang XL, Shang JJ, Ren J, Fan J, Feng XQ, Zhang RW, Xia ZB, Duan XW. Cytokine Profiling in Chinese SLE Patients: Correlations with Renal Dysfunction. J Immunol Res 2020;2020:8146502. [PMID: 33134397 DOI: 10.1155/2020/8146502] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
10 Ghafouri-Fard S, Shahir M, Taheri M, Salimi A. A review on the role of chemokines in the pathogenesis of systemic lupus erythematosus. Cytokine 2021;146:155640. [PMID: 34252872 DOI: 10.1016/j.cyto.2021.155640] [Reference Citation Analysis]
11 Quan W, An J, Li G, Qian G, Jin M, Feng C, Li S, Li X, Xu Y, Hu X. Th cytokine profile in childhood-onset systemic lupus erythematosus. BMC Pediatr 2021;21:187. [PMID: 33882880 DOI: 10.1186/s12887-021-02659-3] [Reference Citation Analysis]
12 Jiang Y, Zhao Y, Liu Y, Huang Q, Meng W, Xu H, Mo X. Imbalanced Innate Lymphoid Cells are Associated With Disease Activity and Arthritis Involvement in Patients With Systemic Lupus Erythematosus. Arch Rheumatol 2020;35:521-32. [PMID: 33758809 DOI: 10.46497/ArchRheumatol.2020.7440] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
13 Park J, Jang W, Park HS, Park KH, Kwok SK, Park SH, Oh EJ. Cytokine clusters as potential diagnostic markers of disease activity and renal involvement in systemic lupus erythematosus. J Int Med Res 2020;48:300060520926882. [PMID: 32489126 DOI: 10.1177/0300060520926882] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
14 Zian Z, Bouhoudan A, Mourabit N, Azizi G, Bennani Mechita M. Salivary Cytokines as Potential Diagnostic Biomarkers for Systemic Lupus Erythematosus Disease. Mediators Inflamm 2021;2021:8847557. [PMID: 33776578 DOI: 10.1155/2021/8847557] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
15 Szymczak F, Colli ML, Mamula MJ, Evans-Molina C, Eizirik DL. Gene expression signatures of target tissues in type 1 diabetes, lupus erythematosus, multiple sclerosis, and rheumatoid arthritis. Sci Adv 2021;7:eabd7600. [PMID: 33523973 DOI: 10.1126/sciadv.abd7600] [Cited by in Crossref: 5] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
16 López-Villalobos EF, Muñoz-Valle JF, Palafox-Sánchez CA, García-Arellano S, Martínez-Fernández DE, Orozco-Barocio G, García-Espinoza JA, Oregon-Romero E. Cytokine profiles and clinical characteristics in primary Sjögren´s syndrome patient groups. J Clin Lab Anal 2021;35:e23629. [PMID: 33070375 DOI: 10.1002/jcla.23629] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
17 Yang B, Zhao M, Wu H, Lu Q. A Comprehensive Review of Biological Agents for Lupus: Beyond Single Target. Front Immunol 2020;11:539797. [PMID: 33123125 DOI: 10.3389/fimmu.2020.539797] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
18 Li D, Yoshida K, Feldman CH, Speyer C, Barbhaiya M, Guan H, Solomon DH, Everett BM, Costenbader KH. Initial disease severity, cardiovascular events and all-cause mortality among patients with systemic lupus erythematosus. Rheumatology (Oxford) 2020;59:495-504. [PMID: 31321417 DOI: 10.1093/rheumatology/kez288] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
19 Wu Q, Cao F, Tao J, Li X, Zheng SG, Pan HF. Pentraxin 3: A promising therapeutic target for autoimmune diseases. Autoimmun Rev 2020;19:102584. [PMID: 32534154 DOI: 10.1016/j.autrev.2020.102584] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
20 Sag E, Demir S, Ozen S. Clusters in Pediatric Rheumatic Diseases. Curr Rheumatol Rep 2020;22:28. [PMID: 32436006 DOI: 10.1007/s11926-020-00908-5] [Reference Citation Analysis]
21 Abji F, Lee KA, Pollock RA, Machhar R, Cook RJ, Chandran V, Gladman DD. Declining levels of serum chemokine (C-X-C motif) ligand 10 over time are associated with new onset of psoriatic arthritis in patients with psoriasis: a new biomarker? Br J Dermatol 2020;183:920-7. [PMID: 32037514 DOI: 10.1111/bjd.18940] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
22 Howe HS, Leung BPL. Anti-Cytokine Autoantibodies in Systemic Lupus Erythematosus. Cells 2019;9:E72. [PMID: 31892200 DOI: 10.3390/cells9010072] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
23 Ruchakorn N, Ngamjanyaporn P, Suangtamai T, Kafaksom T, Polpanumas C, Petpisit V, Pisitkun T, Pisitkun P. Performance of cytokine models in predicting SLE activity. Arthritis Res Ther 2019;21:287. [PMID: 31842967 DOI: 10.1186/s13075-019-2029-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 24] [Article Influence: 3.0] [Reference Citation Analysis]
24 Miyabe Y, Lian J, Miyabe C, Luster AD. Chemokines in rheumatic diseases: pathogenic role and therapeutic implications. Nat Rev Rheumatol 2019;15:731-46. [PMID: 31705045 DOI: 10.1038/s41584-019-0323-6] [Cited by in Crossref: 21] [Cited by in F6Publishing: 33] [Article Influence: 7.0] [Reference Citation Analysis]
25 Zhang R, Li Y, Pan B, Li Y, Liu A, Li X. Increased expression of hub gene CXCL10 in peripheral blood mononuclear cells of patients with systemic lupus erythematosus. Exp Ther Med 2019;18:4067-75. [PMID: 31616519 DOI: 10.3892/etm.2019.8013] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]